Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
Appointed director
Sonoma Pharmaceuticals, Inc. (SNOA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
10/11/2023 8-K/A Quarterly results
10/11/2023 8-K Quarterly results
09/28/2023 8-K Quarterly results
07/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/21/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/14/2023 8-K Quarterly results
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/10/2023 8-K Investor presentation
Docs: "Investor Presentation as of May 10, 2023"
04/13/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
04/13/2023 8-K Quarterly results
02/24/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/24/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment to At-The-Market Offering Agreement, by and between the Company and Ladenburg Thalmann & Co. Inc.",
"Opinion of Burns & Levinson, LLP"
01/31/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "EXCLUSIVE DISTRIBUTION AND SUPPLY AGREEMENT"
01/06/2023 8-K Investor presentation
Docs: "INVESTOR PRESENTATION"
12/30/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/30/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/30/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/30/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/30/2022 4 MCLAUGHLIN JOHN (Director) has filed a Form 4 on Sonoma Pharmaceuticals, Inc.
Txns: Granted 20,000 options to buy @ $1.08, valued at $21.6k
12/30/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/30/2022 8-K Quarterly results
12/23/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "AT THE MARKET OFFERING AGREEMENT",
"OPINION OF BURNS & LEVINSON, LLP"
12/23/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/12/2022 3 White Chad Norman (Interim CFO) has filed a Form 3 on Sonoma Pharmaceuticals, Inc.
10/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "OFFER LETTER"
09/16/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/22/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/22/2022 8-K Quarterly results
07/13/2022 10-K Annual Report for the period ended March 31, 2022
06/29/2022 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy